Citations

Institution: Mayo Clinic Clear

Showing 10 of 108083 citations.

Opioid prescribing trends and pain scores among adult patients with cancer in a large health system
Baum, Laura Van Metre , Soulos, Pamela R. , Ruddy, Kathryn J. , Lerro, Catherine C. , Graham, David J. , Rivera, Donna R. , Liberatore, Mark, Jairam, Vikram , Gross, Cary P. , Park, Henry S. , Ruddy, Kathryn J , Leapman, Michael S , Gross, Cary P , Park, Henry S , KC, Madhav , Jeffery, Molly Moore , Lee, Hana , Leapman, Michael , Dinan, Michaela A.

Cancer | September 22, 2025 | Volume: 131 | Issue: 19 | Pages: No page available

10.1002/cncr.70027 | PMID 40977160 Get It

Abstract Background Opioid stewardship policies could adversely affect pain management for patients with cancer. Yet patients with cancer are also at risk for opioid‐related harms. This study sought to determine trends in opioid prescribing by clinical stratum and pain for patients with cancer from 2016 to 2020. Methods A retrospective study was conducted of opioid‐naive adults with newly diagnosed cancer from 2016 to 2020 ( N = 10,232) in a large Connecticut health system. Logistic regression was used to calculate changes in the predicted probability of opioid prescribing from 2016 to 2020. Two subpopulations were examined: patients treated surgically ( n = 4405) and patients with metastatic cancer ( n = 2158). Flowsheet pain scores for patients with metastatic cancer were used to stratify by no pain (all scores, 0) versus any pain. The main outcomes were new (≥1 prescription in the 0–6 months after diagnosis) and additional (0–6 and 7–9 months) opioid prescriptions. Results A decline was observed in the predicted probability of new (71.1% to 64.6%; p < .001) and additional prescribing (27.2% to 24.2%; p = .07 [not significant]) declined. Among surgical patients, the predicted probability of new opioid prescribing fell (96.0% to 88.6%; p < .001), whereas additional prescribing was stable (13%). For patients with metastatic cancer with pain, new opioid prescribing was stable (56%). For those reporting no pain, the predicted probability of new opioid prescribing declined from 61.6% to 36.1% ( p < .001). Conclusions In the context of widespread policy changes, this study showed a modest decline in new and additional opioid prescribing for patients with cancer. In metastatic cancer, prescribing remained stable for patients reporting pain and declined steeply for those reporting no pain.
Supporting cancer research on real-world data: extracting colorectal cancer status and explicitly written TNM stages from free-text imaging and histopathology reports
Tamm, Andres , Jones, Helen , Doshi, Neel , Perry, William , Withers, Joshua, Salih, Hizni , Noble, Theresa , Little, Stephanie , Roadknight, Gail , Campell, D.J., Matharu, Sheila, Teare, Marion, Galdikas, A., Papadimitriou, Dimitri , Scanlon, Lauren , Woods, Kerrie , Cunningham, Chris , Roadknight, Gail , Perry, William R , Várnai, Kinga A. , Matharu, Sheila, Starling, Naureen , Teare, Marion, Galdikas, Algirdas, Glampson, Ben , Mercuri, Luca , Wasan, Harpreet , Malcomson, Lee , O’Hara, Catherine M. , Renehan, Andrew G. , Nicholson, Brian D , Davies, Jim , Morris, Eva J.A. , Cunningham, Chris

BMJ Health & Care Informatics | September 22, 2025 | Volume: 32 | Issue: 1 | Pages: e101521

10.1136/bmjhci-2025-101521 | PMID 40983364 Get It

Objectives The ‘tumour, node, metastasis’ (TNM) classification of colorectal cancer (CRC) predicts prognosis and so is vital to consider in analyses of patterns and outcomes of care when using electronic health records. Unfortunately, it is often only available in free-text reports. This study aimed to develop regex-based text-processing algorithms that identify the reports describing CRC and extract the TNM staging at a low computational cost. Methods The CRC and TNM extraction algorithms were iteratively developed using 58 634 imaging and pathology reports of patients with CRC from the Oxford University Hospitals (OUH) and Royal Marsden (RMH) NHS Foundation Trusts (FT), with additional input from Imperial College Healthcare and Christie NHS FTs. The algorithms were evaluated on a stratified random sample of 400 OUH development data reports and 400 newer ‘unseen’ OUH reports. The reports were annotated with the help of two clinicians. Results The CRC algorithm achieved at least 93.0% positive predictive value (PPV), 72.1% sensitivity, 64.0% negative predictive value (NPV) and 90.1% specificity for primary CRC on pathology reports. On imaging reports, it demonstrated at least 78.0% PPV, 91.8% sensitivity, 93.0% NPV and 80.9% specificity. For the main T/N/M categories, the TNM algorithm achieved PPVs of at least 93.9% (T), 97.7% (N) and 97.2% (M), and sensitivities of 63.6% (T), 89.6% (N) and 64.8% (M). NPVs were at least 45.0% (T), 91.1% (N), 88.4% (M), and specificities 95.7% (T), 98.1% (N), 99.3% (M). Reductions in performance were mostly due to implicit staging. For extracting explicit TNM stages, current or historical, the algorithm made no errors on 400 pathology reports and six errors on 400 imaging reports. Conclusion The TNM algorithm accurately extracts explicit TNM staging, but other methods are needed for retrieving implicit stages. The CRC algorithm is accurate on non-supplementary reports, but outputs need additional review if higher precision is required.
Midclavicle block: more than a change of name
Labandeyra, Hipólito , D’Souza, Ryan S. , Valdés-Vilches, Luis Fernando , D'Souza, Ryan S

Regional Anesthesia & Pain Medicine | September 22, 2025 | Volume: No volume available | Issue: No issue available | Pages: rapm-2025-107180

10.1136/rapm-2025-107180 | PMID 40983371 Get It

Portohepatic fusion mimics biliary aplasia
El‐Gohary, Yousef , Moir, Christopher R. , Zarroug, Abdalla E.

BMJ Case Reports | September 22, 2025 | Volume: 18 | Issue: 9 | Pages: e266981

10.1136/bcr-2025-266981 | PMID 40983349 Get It

We report a rare case of biliary aplasia in an infant who presented with persistent jaundice and elevated direct bilirubin despite having cholic stools. Imaging confirmed the absence of extrahepatic bile ducts, consistent with biliary atresia. Intraoperatively, there was a complete absence of an extrahepatic biliary tree consistent with biliary hypoplasia. We identified a cryptogenic hepatic plate directly fused to the right portal vein on further dissection. Despite the atypical anatomy, a modified Kasai portoenterostomy was successfully performed. The patient showed progressive clinical improvement with complete resolution of jaundice and normalisation of liver function tests over the following months. This case underscores a rare anatomical variant that can still permit a favourable outcome with a timely Kasai procedure. To our knowledge, this is one of the few documented cases of hepatic plate–portal vein fusion in biliary atresia.
Impact of patisiran on polyneuropathy of hereditary transthyretin amyloidosis in patients with a V122I or T60A variant: a phase IV multicenter study
Hussain, Yessar, Malhotra, Saurabh , Sperry, Brett W. , Shu, Francy , Ananthasubramaniam, Karthikeyan , Desai, Urvi , Egolum, Ugochukwu , Fernandez, Joel , Freimer, Miriam , Mauricio, Elizabeth A. , Quan, Dianna , Small, Roy S., Capocelli, Kelley E. , Roblin, Steven, Bender, Shaun , Jay, Patrick Y. , Yureneva, Elena, Zolty, Ronald , Mauricio, Elizabeth A. , Capocelli, Kelley , Sperry, Brett W

Annals of Medicine | September 20, 2025 | Volume: 57 | Issue: 1 | Pages: No page available

10.1080/07853890.2025.2537347 | PMID 40974604 Get It

Sex differences in chemotherapy completion, toxicities, and survival in colon cancer: an analysis of 2201 patients from CALGB/SWOG 80702 (Alliance)
Cheng, En , Shi, Qian , Shields, Anthony F. , Xue, Xiaonan , Rohan, Thomas E. , Kuang, Chaoyuan , Shergill, Ardaman , Ma, Chao , Couture, Felix, Kuebler, J. Philip , Kumar, Pankaj , Krishnamurthi, Smitha , Ng, Kimmie , Meyerhardt, Jeffrey A. , Krishnamurthi, Smitha , Ng, Kimmie , O'Reilly, Eileen M , Brown, Justin C , Meyerhardt, Jeffrey A , Shi, Qian , Couture, Felix, Kumar, Pankaj , Tan, Benjamin, O’Reilly, Eileen M. , Brown, Justin C. , Cheng, En

JNCI: Journal of the National Cancer Institute | September 20, 2025 | Volume: 117 | Issue: 12 | Pages: 2643-2652

10.1093/jnci/djaf281 | PMID 40996326 Get It

Abstract Background Completing adjuvant chemotherapy and reducing toxicities are critical for maximizing survival after a colon cancer diagnosis. Sex, as a biological variable, may affect colon cancer chemotherapy completion, toxicities, and survival differently. Methods From a National Cancer Institute–sponsored trial conducted among patients with stage III colon cancer (Cancer and Leukemia Group B (Alliance)/Southwest Oncology Group 80702), we included 2201 patients receiving the standard adjuvant chemotherapy regimen of fluorouracil, leucovorin, and oxaliplatin. We calculated relative dose intensity to indicate chemotherapy completion and considered reduced relative dose intensity (values &lt;85%) as a clinically significant deviation from standard fluorouracil, leucovorin, and oxaliplatin. Using National Cancer Institute’s Common Terminology Criteria for Adverse Events, we defined severe adverse events (grade ≥3) as the occurrence of any following event, including neutrophil count decrease, nausea, platelet count decrease, hypertension, peripheral neuropathy, diarrhea, fatigue, gastritis, creatinine level increase, gastric ulcer, myocardial ischemia, and cerebral ischemia. The primary survival outcome was disease-free survival (time from enrollment to colon cancer recurrence or death from any cause), and secondary survival outcomes were recurrence-free and overall survival. Results Compared with men, women were at statistically significantly higher risks of experiencing reduced relative dose intensity (adjusted odds ratio = 1.59, 95% CI = 1.29 to 1.96; P &lt; .001) and severe advance events (adjusted odds ratio = 1.72, 95% CI = 1.41 to 2.11; P &lt; .001). Yet, women had statistically significantly better disease-free survival (adjusted hazard ratio = 0.72, 95% CI = 0.59 to 0.87; P &lt; .001) as well as better recurrence-free and overall survival. Conclusions Our findings suggested that women with colon cancer are more likely to have worse chemotherapy completion rates and more severe adverse events, but they have better survival. Sex as a biological variable warrants further consideration in chemotherapy administration and survivorship management after colon cancer diagnosis.
Monoclonal gammopathy associates with kidney failure in ANCA-associated vasculitis
Vargas-Brochero, Maria J. , Russo, Ilario , Buglioni, Alessia , Zand, Ladan , Domingues, Patricia , Mekraksakit, Poemlarp , Inácio, António , Radhakrishnan, Yeshwanter

Nephrology Dialysis Transplantation | September 20, 2025 | Volume: 41 | Issue: 4 | Pages: 692-702

10.1093/ndt/gfaf195 | PMID 40982230 Get It

ABSTRACT Background Up to 20% of patients with antineutrophil cytoplasmic antibody–associated vasculitis (AAV) and kidney involvement progress to end-stage kidney disease (ESKD) despite therapy. The role of monoclonal gammopathy (MG) in disease progression in patients with AAV is not well understood. Methods We conducted a retrospective study to identify patients diagnosed with AAV and renal involvement who had undergone monoclonal protein testing between November 1999 and December 2023. A total of 167 patients were included in the renal survival analysis and were categorized into monoclonal positive (n = 34) and monoclonal negative (n = 133) groups. For the mortality analysis, we expanded the cohort to include an additional 26 patients who were dialysis-dependent at baseline and remained on dialysis throughout follow-up, resulting in a total of 193 patients. We performed multivariate Cox analysis to identify predictors of adverse renal events [&gt;40% decline in estimated glomerular filtration rate (eGFR) or ESKD (eGFR &lt;15 mL/min/1.73 m², need for dialysis or transplantation)] and mortality. Results Median age of the cohort was 68 (58.5–74.5) years, with 50.8% males, 65.8% MPO positive, and 64.6% receiving rituximab as induction therapy. After adjusting for baseline proteinuria, sclerotic Berden class and induction therapy, MG was associated with adverse renal events [hazard ratio (HR) 3.29 (95% confidence interval 1.12–9.68), P = .03]. MG at baseline was not associated with mortality [HR 1.65 (0.87–3.12), P = .12], however patients with persistent MG at 6 months had higher mortality compared with those without MG or those whose MG was not sustained [HR 3.95 (1.10–14.21), P = .035]. Conclusions Patients with AAV and renal involvement who have MG are at significantly increased risk of adverse renal events even after adjusting for factors such as eGFR and degree of chronicity (known predictors of poor renal outcome). The exact mechanism by which MG portends poor outcomes is poorly understood, and additional research is required.
Factors associated with sleep disturbance in breast cancer survivors over time
Marell, Paulina S. , Vierkant, Robert A. , Larson, Nicole L. , Ehlers, Shawna L. , Donovan, Kristine A. , D’Andre, Stacy D, Couch, Fergus J. , Ruddy, Kathryn J. , D'Andre, Stacy D, Ruddy, Kathryn J , Vierkant, Robert A , Stan, Daniela , Couch, Fergus J. , Olson, Janet E.

The Oncologist | September 20, 2025 | Volume: 30 | Issue: 10 | Pages: No page available

10.1093/oncolo/oyaf297 | PMID 40974175 Get It

Abstract Background Breast cancer (BC) survivors frequently experience sleep disturbances, which may persist for many years after treatment. This study aimed to describe trends in sleep-related symptoms over time and identify factors that may be associated with sleep disturbances in BC survivors. Patients and Methods Adult patients from the Mayo Clinic Breast Disease Registry were surveyed annually for up to 7 years post-diagnosis. Sleep disturbance severity was assessed using numeric rating scales for difficulty falling and staying asleep. Data from 3354 unique patients were analyzed, excluding those with metastatic disease or recurrence. Univariable and multivariable analyses were performed at the 1-year survey timepoint to evaluate disease and patient-related factors that were associated with increased sleep-related symptoms, and these factors were also assessed in relationship to sleep-related symptoms over time. Results In multivariable analyses, more trouble falling asleep was associated with financial insecurity, higher clinical stage, more cigarettes smoked per day, and less weekly exercise. More trouble staying asleep was associated with older age, race, advanced education, financial insecurity, and higher clinical stage. Over time, there was a nonsignificant trend toward increased trouble falling asleep and fluctuations in trouble staying asleep. Higher clinical stage and receipt of radiotherapy were associated with decreased severity in trouble falling asleep over time, while more cigarettes smoked per day was linked to increased severity in trouble staying asleep. Conclusions These findings highlight the complex interplay of clinical, lifestyle, and demographic factors in sleep disturbances among BC survivors, underscoring the need for tailored sleep management strategies.
First-line atezolizumab/bevacizumab or durvalumab/tremelimumab in advanced hepatocellular carcinoma: a real world, multicenter retrospective study
Kournoutas, Ioannis , Marell, Paulina S. , Peersen, Anina, Shah, Priyanshi , VanDommelen, Kyle, Gupta, Garima , Akce, Mehmet , Yang, Ju Dong , Chen, Pin‐Jung , Naleid, Nikolas , Peterson, Nicole , Sahai, Vaibhav , Halfdanarson, Thorvardur, Kankeu, Lionel Fonkoua, Washburn, Leslie, Conboy, Caitlin B. , Goenka, Ajit H. , Thompson, Scott A. , Ahn, Daniel H. , Jatoi, Aminah , Marell, Paulina, Gile, Jennifer , Yang, Ju Dong , Sahai, Vaibhav , Jin, Zhaohui , Fonkoua, Lionel Aurelien A Kankeu , Washburn, Leslie A, Goenka, Ajit, Starlinger, Patrick , Roberts, Lewis, Jatoi, Aminah , Ou, Fang-Shu , Tran, Nguyen , Conboy, Caitlin B , Kamath, Suneel Deepak , Mahipal, Amit , Wee, Wen , Jin, Zhaohui , Fonkoua, Lionel Aurelien Kankeu , Torbenson, Michael , Thompson, Scott, Venkatesh, Sudhakar K. , Starlinger, Patrick , Roberts, Lewis R. , Gores, Gregory J. , Babiker, Hani M. , Borad, Mitesh J. , Bekaii‐Saab, Tanios , McWilliams, Robert R. , Ou, Fang‐Shu

The Oncologist | September 20, 2025 | Volume: 30 | Issue: 11 | Pages: No page available

10.1093/oncolo/oyaf286 | PMID 40973475 Get It

Abstract Background Unresectable hepatocellular carcinoma (uHCC) is a leading cause of cancer death. FDA-approved first-line systemic therapies include atezolizumab/bevacizumab (atezo/bev) and durvalumab/tremelimumab (durva/treme); however, there is a lack of comparative data. Methods We reviewed outcomes of patients with uHCC who initiated atezo/bev or durva/treme between 2017 and 2024, across six institutions. Overall survival (OS) and time to treatment discontinuation (TTD) were analyzed using the Kaplan–Meier and Cox models, adjusting for baseline characteristics. Results Four hundred fifty-two uHCC pts were included. Median age: 68 years; 77% male; 81% white. Most common etiologies were viral hepatitis (38.9%) and metabolic dysfunction-associated steatohepatitis (19.5%). Disease progression was the primary reason for treatment discontinuation, atezo/bev (56%) and durva/treme (42%). Outcomes were not statistically significant (median OS [month, m]: 14.0 vs 14.6 [P = .66]; median TTD [m]: 4.9 vs 3.9 [P = .42] for atezo/bev vs durva/treme). Outcomes were significantly different between Child-Pugh classes (CP: A, B7, B8/9, C) respectively, median OS(m): 19.0, 6.1, 5.1, 2.0 (P &lt; .001); median TTD(m): 6.1, 2.3, 3.0, 1.3 (P &lt; .001). Conclusions In this real-world study of uHCC, no significant difference in clinical outcomes was observed between atezo/bev and durva/treme in the first-line setting. CP scores were a key prognostic variable with both regimens.
Telestroke and Emergency Department Imaging: Timing of CT Angiography Within the IV Thrombolytic Decision-Making Sequence
Murray, Nick M. , McKasson, Marilyn , Johnson, Paul D. , Johnson, Trina, Hassler, Jami, Smith, Shawn , Hoesch, Robert, Guidry, David, Johnston, Chamonix, Püttgen, H. Adrian , Johnson, Trina, Demaerschalk, Bart M. , Johnston, Chamonix

The Neurohospitalist | September 20, 2025 | Volume: 16 | Issue: 2 | Pages: 133-139

10.1177/19418744251382291 | PMID 40979633 Get It

Background Telestroke emergency department (ED) workflow emulates that of in-person care, yet limitations of the virtual interaction may require accommodations. The optimal sequence of non-contrast head CT, cerebral CT angiogram, and decision to infuse IV thrombolytic is not defined for telestroke. Methods In this twenty-two-hospital multicenter retrospective study between 1/1/2024-12/31/2024, we characterized timing of ED CT angiograms, either bundled with the non-contrast head CT or non-bundled and performed after the IV-thrombolytic decision. The primary outcome was effect of bundling on door to needle time (DTN) when directed by telestroke. Timing of CT scans was determined by time stamps of scout images. Results In total, 5704 patients were included, with a median age of 65 years (Interquartile range, IQR 58-77) and NIHSS 8 (IQR 6-13). There were 4518 patients in the bundled group (n = 12 hospitals), with time from non-contrast CT to CTA of median 2 min (IQR 0-6 min; vs non-bundled (n = 10 hospitals): 7, 4-15 min; P = .0001). DTN was not statistically different between the groups, bundled vs not: median 47 min (IQR, 35-62 min) vs 54 min (IQR, 41-67 min, P = .21). Door in door out (DIDO) times also were unchanged (169, 117-254 vs 175, 123-247 min; P = .56). These findings, although showing no statistical difference, may have significance for clinical workflows and were consistent with the results of validation analyses conducted on individual patients. Conclusions Bundling non-contrast head CT with the CT angiogram before thrombolytic decision did not delay DTN times, trended to clinically improve times, and may be relevant for telestroke ED workflows.